Group 1 - The company, Kangyuan Pharmaceutical, emphasizes its commitment to addressing unmet clinical needs by focusing on traditional Chinese medicine and biopharmaceuticals with significant clinical value, particularly in areas such as cardiovascular diseases, metabolic disorders, autoimmune diseases, and neurological disorders [2] - The company is advancing its core pipeline of chemical drugs, specifically the Class 1 new drugs KY1701 and KY0467, which are currently in clinical stages, and plans to systematically progress the development of these products according to its existing pipeline [2]